Bladder cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

13 of 13+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €2,000,000· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €197,264· until Mar 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Ireland· EU contribution €328,495· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Ireland· EU contribution €13,615,935· until Dec 2029· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Israel· EU contribution €2,498,731· until Nov 2026

5 of 9 running projects, newest first. Listed amounts together: €36.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

  NCT03150836· Terence Friedlander, MD· Updated 19 Oct 2017

  “Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 77
• Genome-Wide Association Study 18

• Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.

  World J Urol, Oct 2026

• Liquid Biopsies for Cancer: A Translational Science Review.

  JAMA, Sept 2026

• Liquid biopsy in bladder cancer: towards precision oncology.

  J Transl Med, Sept 2026

• Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: A systematic review and reconstructed patient-data meta-analysis.

  Crit Rev Oncol Hematol, Sept 2026

• ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis.

  World J Urol, Aug 2026

  Wajahat Mirza

• The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer.

  Urol Clin North Am, Jul 2026

• Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.

  BJU Int, Jul 2026

• Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

  ESMO Open, Jun 2026

• Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.

  Ann Surg Oncol, Jun 2026

• Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer.

  Mol Oncol, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.